Drugs / CD34+ derived DCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00197522 | Oct 2004 → May 2012 | breast cancer | Hamilton Health Sciences Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD34+ derived DCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00197522 ↗ |
| Modality | Cell therapy | “These transduced DCs are then injected intradermally into the patient.” NCT00197522 ↗ |
| Route | Other | “These transduced DCs are then injected intradermally into the patient.” NCT00197522 ↗ |